About UPTRAVI

Add UPTRAVI as Part of Early Comprehensive Treatment for FC II and FC III PAH

Guidelines Recommendation

2015 ESC/ERS GUIDELINES: UPTRAVI is the only oral prostacyclin pathway therapy to receive the highest class recommendation for sequential combination therapy in FC II and FC III1

THE 6TH WORLD SYMPOSIUM ON PULMONARY HYPERTENSION: Escalation to triple-combination therapy is recommended when the initial treatment approach with double-combination therapy results in an intermediate risk status2

How Uptravi Works

UPTRAVI selectively targets the IP receptor—the key target within the prostacyclin pathway3,4

ESTABLISHED PROSTANOID RECEPTORS IN THE HUMAN PULMONARY ARTERY
*Clinical significance in humans is unknown.